ArticleJournal of hematology & oncology2019

Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells.

Yuanyuan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.